Biosimilars Could Save Taxpayers Billions

A recent analysis conducted by Pacific Research Institute and Wayne Winegarden, PhD, found that if biosimilars reached 75% market share, the federal government would save $7 billion annually, state Medicaid programs would save $1.2 billion annually, and commercial payers would save $3.3 billion annually.

For the study, Winegarden analyzed the savings potential of biosimilars using recent price and volume data. The pricing data were based on national average sales price points from July 2019 through September 2019 and on expenditures-per-unit data from the Centers for Medicare and Medicaid Services (CMS). Volume data came from 12-month sales-volume numbers through February 2019

Leave a Reply